The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) hosted an all-day workshop and annual meeting September 13 and 14 in Washington. The...
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN ( NYSE: QGEN;...
AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announces that U.S. Food and Drug...
Regen BioPharma, Inc. announced initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation approach through pre-clinical...
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, announced that it has acquired XenoTech, a provider of...
